EVALUATION OF THE RESULTS OF ORAL ITRACONAZOLE IN THE TREATMENT OF SEBORRHEIC DERMATITIS AT CAN THO DERMATOLOGY HOSPITAL IN 2019-2021
Main Article Content
Abstract
Background: Seborrheic dermatitis (SD) is a chronic and relapsing disease, topical therapy may be associated with failure, particularly in severe disease. Itraconazole has been suggested as an effective and safe treatment for moderate to severe SD. Objectives: To evaluate the efficacy of oral itraconazole in the treatment of SD at Dermatology Can Tho Hospital from 2019 to 2021. Materials and methods: 80 patients with moderate to severe SD were enrolled at Dermatology Can Tho Hospital and were treated with oral itraconazole. Itraconazole 200 mg daily was prescribed for 2 weeks and then for the first 2 days of every week for the following 4 weeks. Patients were followed for 6 weeks. Subjects’ signs and symptoms of severity (erythema, scaling, pruritus and burning) were rated on a scale of 0-3 (none to severe). Results: After 2 weeks of study, 31.3% of the patients reported a good and very good improvement, 56.2% of the patients reported a moderate improvement and only 12.5% had a slight improvement. However, the proportion of patients with a good and very good improvement consistently increased after 4 and 6 weeks. After completing the regimen, 96.2% of the patients reported a good and very good improvement, none had a slight improvement. No side effects were reported. Conclusion: Itraconazole is an effective and safe therapy for patients with moderate to severe SD.
Keywords
itraconazole, seborrheic dermatitis
Article Details
References
2. Ahman S., Perrins N., Bond R. (2007), Treatment of Malassezia pachydermatis-associated seborrhoeic dermatitis in Devon Rex cats with itraconazole - a pilot study, ESVD and ACVD, 18, pp. 171-174.
3. Baysal V., Yildirim M., Ozcanli C. et al. (2004), Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality, International Journal of Dermatology, 43, pp. 63-66.
4. Cooper S. M., Sheridan A. and Burge S. (2003), Mycosis fungoides responding to systemic itraconazole, Journal of the European Academy of Dermatology and Venereology, 17 (5), pp. 588-590.
5. Faergemann J. (2000), Management of Seborrheic Dermatitis and Pityriasis Versicolor, Am J Clin Dermatol, 1 (2), pp. 75-80.
6. Ghodsi S. Z., Abbas Z., Abedeni1 R. (2015), Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial, Am J Clin Dermatol, 16, pp. 431-437.
7. Gupta A. K., Nicol K., Batra R. (2004), Role of Antifungal Agents in the Treatment of Seborrheic Dermatitis, Am J Clin Dermatol, 5 (6), pp. 417-422.
8. Kose O., Erbil H., Gur A. R. (2005), Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial, J European Academy of Dermatology and Venereology, 19, pp. 172-175.
9. Lestner J., Hope W. W. (2013), Itraconazol: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections, Expert Opin. Drug Metab. Toxicol., 9 (7), pp. 911-926.
10. Shemer A., Kaplan B., Nathansohn N. et al. (2008), Treatment of Moderate to Severe Facial Seborrheic Dermatitis with Itraconazole: An Open Non-Comparative Study, IMAJ, 10, pp. 417-418.
11. Suh D. H. (2019), Seborrheic dermatitis, Fitzpatrick’s Dermatology, Mc Gram Hill Education, pp. 428-437.
12. Tercelj M., Rott T. and Rylander R. (2007), Antifungal treatment in sarcoidosis-a pilot intervention trial, Respiratory medicine, 101 (4), pp. 774-778.
13. Van T. N., Thi N. H., Van T. H. et al. (2019), Efficacy of Oral Itraconazole in the Treatment of Seborrheic Dermatitis in Vietnamese Adults Patients, Open access Macedonian journal of medical sciences, 7 (2), pp. 224-226.
14. V'Lckova‐Laskoska M. T., Caca‐Biljanovska N. G., Laskoski D. S. et al. (2009), Palmoplantar pustulosis treated with itraconazole: a single, active‐arm pilot study, Dermatologic therapy, 22 (1), pp. 85-89.